Pharmacologic Targeting of PDIA1 Inhibits NLRP3 Inflammasome Assembly and Activation

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• The NLRP3 inflammasome is crucial for innate immunity, regulating inflammatory cytokine secretion.
• Its hyperactivation is linked to various diseases, necessitating novel inhibitory strategies.

Purpose of the Study:

• To investigate the proteostasis regulator AA147 as an inhibitor of NLRP3 inflammasome assembly and activation.
• To identify the molecular target of AA147 within the inflammasome pathway.

Main Methods:

• Utilized monocytes and macrophages to assess AA147's effect on NLRP3 inflammasome activity.
• Investigated the mechanism of inhibition, focusing on endoplasmic reticulum (ER) protein modification.
• Employed genetic depletion and selective inhibitors to validate the role of the identified target.

Main Results:

• AA147 inhibits NLRP3 inflammasome activation by impairing inflammasome complex assembly.
• AA147 covalently modifies protein disulfide isomerase A1 (PDIA1) at the ER membrane.
• PDIA1 inhibition, via genetic or chemical means, effectively blocks NLRP3 inflammasome assembly and activation.

Conclusions:

• PDIA1 is identified as a key mediator in NLRP3 inflammasome assembly and activation.
• Targeting PDIA1 presents a promising therapeutic strategy to control NLRP3 inflammasome-driven inflammation in diverse diseases.